title: High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
abstract: The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient cohort. We evaluated the clinical impact of sPD-L1 level measured at the time of diagnosis for newly diagnosed diffuse large B-cell lymphoma (DLBCL). Soluble PD-L1 was measured in the plasma of 288 patients enrolled in a multicenter, randomized phase III trial that compared R-high-dose chemotherapy with R-CHOP. The median follow-up was 41.4 months. A cutoff of 1.52 ng/ml of PD-L1 level was determined and related to overall survival (OS). Patients with elevated sPD-L1 experienced a poorer prognosis with a 3-year OS of 76% versus 89% (P<0.001). Considering clinical characteristics, the multivariate analysis retained this biomarker besides bone marrow involvement and abnormal lymphocyte-monocyte score as independently related to poor outcome. sPD-L1 was detectable in the plasma and not in the serum, found elevated in patients at diagnosis compared with healthy subjects and its level dropped back to normal value after CR. The intention-to-treat analysis showed that elevated sPD-L1 was associated with a poorer prognosis for patients randomized within the R-CHOP arm (P<0.001). Plasma PD-L1 protein is a potent predicting biomarker in DLBCL and may indicate usefulness of alternative therapeutic strategies using PD-1 axis inhibitors.
authors.affiliation: INSERM U917, Université de Rennes 1, Hôpital Universitaire de Rennes, Rennes, France.
authors.forename: D
authors.initials: D
authors.lastname: Rossille
authors.affiliation: INSERM U917, Université de Rennes 1, Hôpital Universitaire de Rennes, Rennes, France.
authors.forename: M
authors.initials: M
authors.lastname: Gressier
authors.affiliation: Centre de Recherche des Cordeliers, INSERM U872, Université Pierre et Marie Curie and Université Paris-Descartes, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Damotte
authors.affiliation: 1] Hospices Civils de Lyon, Service de Biostatistiques, Lyon, France [2] CNRS UMR 5558, Equipe Biostatistique Santé, Pierre-Bénite, France [3] Université Lyon I, Villeurbanne, France.
authors.forename: D
authors.initials: D
authors.lastname: Maucort-Boulch
authors.affiliation: INSERM U917, Université de Rennes 1, Hôpital Universitaire de Rennes, Rennes, France.
authors.forename: C
authors.initials: C
authors.lastname: Pangault
authors.affiliation: INSERM U917, EFS de Bretagne, Rennes, France.
authors.forename: G
authors.initials: G
authors.lastname: Semana
authors.affiliation: Hôpital Universitaire de Nantes, Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.affiliation: Service d'hématologie, Hôpital Henri Mondor, Créteil, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Haioun
authors.affiliation: 1] INSERM U917, Université de Rennes 1, Hôpital Universitaire de Rennes, Rennes, France [2] INSERM U917, EFS de Bretagne, Rennes, France.
authors.forename: K
authors.initials: K
authors.lastname: Tarte
authors.affiliation: INSERM U917, Université de Rennes 1, Hôpital Universitaire de Rennes, Rennes, France.
authors.forename: T
authors.initials: T
authors.lastname: Lamy
authors.affiliation: Université de Bordeaux 2, Hôpital Universitaire de Bordeaux-Pessac, Bordeaux, France.
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.affiliation: INSERM U917, Université de Rennes 1, Hôpital Universitaire de Rennes, Rennes, France.
authors.forename: T
authors.initials: T
authors.lastname: Fest
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000097:blood*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D057194:Intention to Treat Analysis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D060890:B7-H1 Antigen
references.citation: Leukemia. 2014 May;28(5):993-1000
references.pmid: 24153012
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: Eur J Immunol. 2011 Feb;41(2):413-24
references.pmid: 21268011
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71
references.pmid: 23375551
references.citation: Lancet. 1986 Feb 8;1(8476):307-10
references.pmid: 2868172
references.citation: Leuk Res. 2012 Apr;36(4):413-7
references.pmid: 22277681
references.citation: Lancet. 2013 May 25;381(9880):1817-26
references.pmid: 23615461
references.citation: Nature. 2000 Feb 3;403(6769):503-11
references.pmid: 10676951
references.citation: N Engl J Med. 2004 Mar 25;350(13):1287-95
references.pmid: 15044639
references.citation: N Engl J Med. 2002 Jun 20;346(25):1937-47
references.pmid: 12075054
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Annu Rev Immunol. 2008;26:677-704
references.pmid: 18173375
references.citation: Cytokine. 2011 Nov;56(2):231-8
references.pmid: 21733718
references.citation: Blood. 2003 Jun 1;101(11):4279-84
references.pmid: 12576316
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Leukemia. 2007 Jan;21(1):37-43
references.pmid: 17039226
references.citation: Haematologica. 2011 Aug;96(8):1136-43
references.pmid: 21546499
references.citation: Science. 1995 Nov 10;270(5238):985-8
references.pmid: 7481803
references.citation: Nat Med. 2003 May;9(5):562-7
references.pmid: 12704383
references.citation: Annu Rev Immunol. 2001;19:565-94
references.pmid: 11244047
references.citation: J Clin Pathol. 2009 Feb;62(2):128-38
references.pmid: 18794197
references.citation: Methods. 2013 May 15;61(1):10-7
references.pmid: 23603216
references.citation: N Engl J Med. 2010 Apr 15;362(15):1417-29
references.pmid: 20393178
references.citation: Leukemia. 2011 Sep;25(9):1502-9
references.pmid: 21606957
references.citation: Hum Pathol. 2008 Jul;39(7):1050-8
references.pmid: 18479731
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):1915-23
references.pmid: 21355078
references.citation: N Engl J Med. 2013 Oct 31;369(18):1681-90
references.pmid: 24171516
references.citation: J Clin Oncol. 2011 Apr 10;29(11):1452-7
references.pmid: 21383296
references.citation: J Immunol Methods. 2009 Oct 31;350(1-2):125-32
references.pmid: 19748508
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3452-9
references.pmid: 22851565
references.citation: Blood. 2004 Jan 1;103(1):275-82
references.pmid: 14504078
references.citation: J Exp Med. 2003 Sep 15;198(6):851-62
references.pmid: 12975453